Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.

@article{Rordorf2005ClinicalPO,
  title={Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.},
  author={Christiane M Rordorf and Les Choi and Paul Marshall and James B. Mangold},
  journal={Clinical pharmacokinetics},
  year={2005},
  volume={44 12},
  pages={1247-66}
}
Lumiracoxib (Prexige) is a selective cyclo-oxygenase (COX)-2 inhibitor developed for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. Lumiracoxib possesses a carboxylic acid group that makes it weakly acidic (acid dissociation constant [pKa] 4.7), distinguishing it from other selective COX-2 inhibitors. Lumiracoxib has good oral bioavailability (74%). It is rapidly absorbed, reaching maximum plasma concentrations 2 hours after dosing, and is highly plasma protein bound… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…